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OBJECTIVES: To estimate incremental effects of patients’
dependence and function on costs of care during the early
stages of Alzheimer’s disease (AD) and to compare strengths
of their relationships with different cost components.
DESIGN: Multicenter, cross-sectional, observational
study.
SETTING: Three university hospitals in the United States.
PARTICIPANTS: One hundred seventy-nine community-
living patients with probable AD, with modified Mini-
Mental State Examination scores of 30 or higher.
MEASUREMENTS: Patients’ dependence was measured
using the Dependence Scale (DS). Functional capacity was
measured using the Blessed Dementia Rating Scale (BDRS).
Total cost was measured by summing direct medical costs
and informal costs. Direct medical costs included costs
of hospitalization, outpatient treatment and procedures,
assistive devices, and medications. Informal costs were
estimated from time spent helping with basic and instru-
mental activities of daily living for up to three caregivers per
patient using national average hourly earnings as wage rate.
RESULTS: DS and BDRS were associated with higher total
cost; a 1-point increase in DS was associated with a $1,832
increase in total cost, and a 1-point increase in BDRS was
associated with a $3,333 increase. Examining component
costs separately identified potential differences between DS
and BDRS. A 1-point increase in BDRS was associated with
a $1,406 increase in direct medical cost. A 1-point increase
in DS was associated with a $1,690 increase in informal
cost.
CONCLUSION: Patients’ dependence and function related
differently to direct medical and informal cost, suggesting
that measures of function and dependence provided unique
information for explaining variations in cost of care for
patients with AD, highlighting the value in measuring both
constructs. J Am Geriatr Soc 56:1497–1503, 2008.
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A defining feature of Alzheimer’s disease (AD) ispatients’ loss of function. Instruments used in rating
functional deficits in AD typically focus on patients’ ability
to perform self-care tasks.1–4 One of the most frequently
used instruments is the Blessed Dementia Rating Scale
(BDRS),1 but the BDRS and other measures of functional
deficits do not fully assess patients’ dependence on other
individuals due to deterioration in cognition and function.
To address this, the Dependence Scale (DS) has been devel-
oped to directly measure the required amount of assistance
patients with AD need.5 Earlier studies have demonstrated
that patients’ dependence on others indicates aspects of
disability in AD that are related to, but distinct from,
aspects of disability indicated by functional deficit.6–8
The tremendous effect of loss of function on costs of
caring for patients with AD has been clearly established.9–14
In earlier works from the Predictors Study, a large, multi-
center study of patients with probable AD followed from
early stages of the disease, the association between costs of
direct medical care and informal caregiving and patients’
functional status, as measured using the BDRS, was exam-
ined.13,14 Few studies have examined the effect of depen-
dence on costs of care for patients with dementia.15
Whether dependence has an incremental effect on costs of
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care for patients with AD, beyond that from loss of
function, is yet to be determined. Therefore, the goals of this
study were to examine how patients’ dependence on others
relates to total costs of care and components of costs; to
estimate the incremental effect of dependence on costs dur-
ing early stages of AD, independent of loss of function; and
to compare the strengths of the relationships between pa-
tients’ function and dependence and the different compo-
nents of costs of care.
METHODS
Sample
The sample was drawn from the Predictors 2 cohort and
consisted of 204 patients with probable AD recruited
between 1998 and 2004 from three sites: Columbia Uni-
versity Medical Center, Johns Hopkins School of Medicine,
and Massachusetts General Hospital.16,17 Specifically, at
the Columbia site, patients were recruited from the Mem-
ory Disorder Center and from physician’s private practices
through the Alzheimer’s Disease Research Center (ADRC).
At the Johns Hopkins site, patients were recruited from
the ADRC and from several university clinics treating
elderly, cognitively impaired patients. At the Massachusetts
General Hospital site, patients were recruited from the
Geriatric Neurobehavioral Clinic. The inclusion and exclu-
sion criteria are fully described elsewhere.16,17 Briefly, sub-
jects met Diagnostic and Statistical Manual for Mental
Disorders, Third Edition, Revised, criteria for primary de-
generative dementia of the Alzheimer type and National
Institute of Neurological Disorders and Stroke–Alzheimer’s
Disease and Related Disorders Association criteria for
probable AD. Enrollment required a modified Mini-Mental
State Examination (MMSE) score of 30 or higher, equiv-
alent to a score of approximately 16 or higher on the Fol-
stein MMSE.18,19 The appropriate local institutional review
boards approved the study. Because patients were followed
at academic AD centers, they were well characterized, with
high degrees of certainty in their AD diagnosis. One
hundred nine of the patients have had brain autopsies. Post
mortem diagnoses have been completed for 96 patients,
96% of whom had AD-type pathological changes based on
Consortium to Establish A Registry for Alzheimer’s Disease
and National Institute on Aging–Reagan Criteria.20,21
Following earlier work,13,14 15 patients (7.3%) living
in nursing homes were excluded, because patterns of
care use and costs differ substantially for nursing home
patients.22 Nine patients (4.4%) with missing cost data and
one patient with missing Dependence Scale data were
also excluded from the analysis sample. The final analysis
sample consisted of baseline data from 179 patients.
Measures
Patient characteristics and cost outcomes used in this study
are briefly described below. Details of the measures and the
costing methods used were reported in earlier studies.13,14
Cost Outcomes
Patients and informants reported use of four domains of
medical care in the previous year, including hospitalizations,
outpatient treatment and procedures, assistive devices, and
medications. Prices were obtained using public databases,
as described in detail in earlier reports. All cost values were
adjusted to constant 2005 dollars using the medical care
component of the Consumer Price Index. Information
about informal caregiving time for activities of daily living
(ADLs) and instrumental activities of daily living (IADLs)
and for supervision was obtained from up to three caregiv-
ers (primary and two secondary caregivers) for each patient.
ADLs included eating, dressing, and personal care. IADLs
included shopping, chores, personal business, and trans-
portation. Hours of informal care provided per day for each
caregiving task were asked about in the following catego-
ries: 0, up to 3 hours, 3 to 6 hours, 6 to 9 hours, 9 to 12
hours, and more than 12 hours. The categories were trans-
formed into continuous values using the mean of each cat-
egory as the estimated hours of care provided. For subjects
who reported more than 12 hours per day for a particular
type of task, the values were top-coded to 12 hours. Total
hours of care provision for IADL and ADL tasks were top-
coded at 16 hours to provide 8 hours of sleep for the care-
givers.23 No caregiver provided more than 16 hours of care
per day at baseline. The hours reported for each task were
summed to obtain an estimate of total caregiving hours each
patient received. The national average hourly earning for all
private industries for each year was used as the hourly wage
rate to estimate unpaid caregiving costs.24 Total cost of care
was estimated by summing costs of direct medical care and
informal caregiving costs.
Dependence Scale
The DS consists of 13 items representing a wide range of
levels of care required by a patient, from subtle items such
as needing reminders or advice to more gross forms such as
needing to be fed.5 All items address patients’ needs. In
some cases, the need is only for supervision, without any
specific tasks linked to the need. The instrument is designed
to be administered to a reliable informant who lives with
the patient or one who is well informed about the patient’s
daily activities and needs. With the exception of the first
two items (needs reminders to manage chores, needs help to
remember important things such as appointments), which
are coded as 0 (no), 1 (occasionally, at least once a month),
and 2 (frequently, at least once a week), responses to the rest
of the items are coded dichotomously and indicate whether
the patient requires assistance in a particular item (05no,
15 yes). The total DS score is the sum of scores on all 13
items (range 0–15) and provides a continuous index of
progressively greater dependence on others. Reliability and
validity of the scale have been established in earlier studies,
with reliability coefficients ranging between 0.66 and 0.93.5
For ease of presenting descriptive results, the sample was
stratified into quartiles based on the total DS score, with the
first quartile representing the lowest level of dependence
and the highest quartile the most severe level of dependence.
Functional Assessment
Functional capacity was measured using the BDRS Part I
(IADLs) and Part II (ADLs).1 The following IADL items are
included in the BDRS: difficulty performing chores around
the house (e.g., cleaning), handling money, remembering
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short lists (e.g., shopping), walking across a room, walking
several blocks, recognizing one’s whereabouts, and remem-
bering things that happened recently. The response options
for these items were none (0), some difficulty (0.5), and a lot
of difficulty (1). The following three ADL items are in-
cluded: eating, dressing, and bladder and bowel control.
The response options for these items ranged from 0 to 3,
with higher score indicating more difficulty. For example,
for the item on eating, the response options were eat cleanly
(0), messily or only with a spoon (1), only able to eat simple
solids such as pudding (2), and need to be fed (3). The total
BDRS score is the sum of scores on all 10 items (range
0–17), with higher scores indicating worse functional
status. Reliability and validity of the scale have been estab-
lished in earlier studies, with reliability coefficients between
0.60 and 0.80.1
Other Clinical and Demographic Characteristics
In addition to measures of dependence and function, several
other clinical and demographic characteristics were obtained
in the study. Disease progression was characterized accord-
ing to transition from milder stages of dementia to more-
severe stages, measured according to the MMSE.18 Lower
MMSE scores indicate worse cognitive status. Columbia
University Scale for Psychopathology in Alzheimer’s Disease,
a semistructured interview administered by a physician or
a trained research technician, was used to measure patients’
psychotic, behavioral, and depressive symptoms.25,26 The
Unified Parkinson’s Disease Rating Scale was used to mea-
sure extrapyramidal signs (EPSs).26–28 Patients’ medical
histories were used to construct a modified version of
the Charlson Comorbidity Index.29 Comorbid conditions
included myocardial infarct, congestive heart failure,
peripheral vascular disease, hypertension, chronic obstruc-
tive pulmonary disease, arthritis, gastrointestinal diseases,
mild liver disease, diabetes mellitus, chronic renal disease,
and systemic malignancy. No patients reported clinical
strokes, metastatic tumors, or acquired immunodeficiency
syndrome at baseline. Patients’ age, ethnicity, sex, highest
level of education, and marital status were also recorded.
Analysis
Patient characteristics were compared across the DS score
quartiles. Comparisons of categorical variables were per-
formed using chi-square tests, and comparisons of contin-
uous variables were performed using analyses of variance.
Following previous work, separate equations were esti-
mated for total costs, direct medical costs, and informal
caregiving costs using generalized linear models.13,14
The independent variables fell into three groups: main
independent variables (DS and BDRS scores), other clinical
variables (e.g., MMSE), and demographic variables. Be-
cause there was concern about possible collinearity between
the main independent variables and other clinical variables,
two sets of models were estimated for each equation: a full
model, which controlled for all clinical and demographic
variables in addition to the main independent variables,
and a trimmed model, which controlled only for the demo-
graphic variables in addition to the main independent vari-
ables. It was decided to present results from the trimmed
models rather than the full models for the following
reasons. Aside from depressive symptoms and comorbidi-
ty index, the excluded clinical variables were highly corre-
lated with DS and BDRS. (Correlations between the
excluded clinical variables with DS ranged from  0.28
for the MMSE to 0.20 for EPSs, and with BDRS ranged
from 0.15 for behavioral problems to 0.25 for EPS.) The
individual clinical variables were not statistically significant
in the estimating models, and coefficient estimates for DS
and BDRS in the full models were not substantially different
from those in the trimmed models. Comparison of the
Akaike Information Criterion and the Bayesian Informa-
tion Criterion suggests that the trimmed models performed
as well as the full models. Results of the full models are
available upon request. The effect of an interaction term for
DS and BDRS was also examined. Results showed that the
interaction term was not statistically significant in any of
the models, so it was dropped from the final specification.
All analyses were performed using Stata 9.0 (Stata Corp.,
College Station, TX).
RESULTS
Baseline demographic and clinical characteristics of the
patients are summarized in Table 1 and compared across DS
quartiles. Because of the study inclusion criteria, patients
were at early stages of AD. The typical patient was female
(58%), aged 76, white, and had more than 14 years of
education. The average DS score  standard deviation was
5.2  2.2, indicating a mild level of dependence. Almost
one-quarter of the patients (23.5%) had DS scores of 3 or
lower; another 31.2% had DS scores between 4 and 5; the
modal DS score was 6 (24.0%), and the rest had DS scores
between 7 and 12 (21.2%). At baseline, no patient had a DS
score above 12. The average MMSE score in this sample
was 22.1  3.6, and the average BDRS score was 3.5  2.1.
Although almost all patients had some IADL limitations
(98.8%), 64.0% were not limited in ADLs. Behavioral
problems were common (41.6%). Approximately one-third
(30.2%) had psychotic symptoms, 20.5% had depressive
symptoms, and 14.5% had EPSs. On average, patients had
less than one comorbid condition (mean 0.8  0.9); 47.8%
did not have any comorbid conditions. The most prevalent
comorbid conditions included hypertension (36.9%), dia-
betes mellitus (9.6%), and myocardial infarction (6.2%).
During the previous year, patients averaged less than one
hospitalization (mean 0.3  0.6), two outpatient treat-
ments or procedures (mean 2.0  2.1), one assistive device
(mean 1.2  1.1), and four medications (mean 3.8  1.5).
Although patients were at early stages of AD, they received
an average of 20.7  24.0 hours of informal care a week.
Data in Table 1 show that DS was related to other
clinical characteristics in expected ways and suggest that DS
captures global severity and various aspects of the disease.
Aside from depressive symptoms, DS was strongly associ-
ated with all other clinical characteristics included in the
analysis. Specifically, patients with more-severe levels of
dependence were older (P5.001); had more functional
limitations (Po.001), worse MMSE scores (Po.001), and
more comorbidities (P5.006); and were more likely to ex-
hibit behavioral problems (P5.02), EPSs (P5.005), and
psychotic symptoms (P5.007). In addition, patients with
more-severe levels of dependence had more outpatient
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treatments and procedures (P5.02) and more assistive de-
vices (Po.001) and received more informal caregiving time
(P5.02).
Unadjusted Costs
At baseline, almost all patients used some medical care
(98.3%, n5 176) and informal care (93.9%, n5168). Av-
erage annual direct medical costs were estimated at $8,675
and informal costs at $18,440 ( 19 h/wk). Figure 1 plots
reported average annual direct medical costs and informal
costs according to DS score quartiles. Total costs and
informal costs were significantly higher in patients in higher
DS score quartiles (P5.03 and .04).
Adjusted Costs
Table 2 presents multivariate regression results of patient
characteristics on total costs, direct medical costs, and
informal costs. The DS and BDRS were entered into the
model as continuous variables and were significantly asso-
ciated with higher total costs: A 1-point increase on the DS
was associated with a $1,832 increase in total costs, and a
1-point increase on the BDRS was associated with a $3,333
increase in total costs. Examining direct medical costs and
informal costs separately identified potential differences
between the DS and BDRS. Direct medical costs were
significantly associated with BDRS: a 1-point increase on
the BDRS was associated with a $1,406 increase in direct
medical costs. However, informal costs were significantly













Female, n (%) 104 (58.1) 28 (66.7) 30 (53.6) 23 (53.5) 23 (60.5)
Age
Mean  SD 76.03  8.0 72.83  7.7 75.41  7.3 76.77  8.8 79.63  7.1
o65, n (%) 16 (8.9) 6 (14.3) 4 (7.1) 5 (11.6) 1 (2.6)
65–74, n (%) 51 (28.5) 18 (42.9) 21 (37.5) 6 (14.0) 6 (15.8)
75–84, n (%) 88 (49.2) 17 (40.5) 25 (44.6) 24 (55.8) 22 (57.9)
85, n (%) 24 (13.4) 1 (2.4) 6 (10.7) 8 (18.6) 9 (23.7)
Race, n (%)
White 171 (95.5) 40 (95.2) 54 (96.4) 40 (93.0) 37 (97.4)
Other 8 (4.5) 2 (4.8) 2 (3.6) 3 (7.0) 1 (2.6)
Years of schooling completed
Mean  SD 14.37  3.1 14.83  3.5 14.64  3.3 14.40  2.8 13.42  2.7
o12, n (%) 17 (9.5) 4 (9.5) 7 (12.5) 3 (7.0) 3 (7.9)
12, n (%) 60 (33.5) 13 (31.0) 15 (26.8) 14 (32.6) 18 (47.4)
13–15, n (%) 28 (15.6) 4 (9.5) 8 (14.3) 10 (23.3) 6 (15.8)
16, n (%) 74 (41.3) 21 (50.0) 26 (46.4) 16 (37.2) 11 (28.9)
Blessed Dementia Rating Scale score (range 0–17),
mean  SD
3.50  2.1 1.69  1.1 2.91  1.1 4.05  1.5 5.75  2.3
Mini-Mental State Examination score (range 0–30),
mean  SD
22.12  3.6 23.55  3.2 22.64  4.0 21.33  3.6 20.68  2.6
Behavioral problems, n (%) 74 (41.6) 21.4 ((9) 24 (43.6) 21 (48.8) 20 (52.6)
Extrapyramidal signs, n (%) 25 (14.5) 4 (10.0) 2 (3.6) 4 (9.8) 15 (40.5)
Depressive symptoms, n (%) 36 (20.5) 5 (11.9) 15 (27.8) 7 (16.3) 9 (24.3)
Psychotic symptoms, n (%) 54 (30.2) 5 (11.9) 17 (30.4) 14 (32.6) 18 (47.4)
Number of comorbidities
Mean  SD 0.78  0.9 0.48  0.8 0.71  0.9 0.95  1.0 1.03  0.9
0, n (%) 85 (47.8) 29 (69.0) 30 (53.6) 15 (34.9) 11 (29.7)
1, n (%) 61 (34.3) 8 (19.0) 15 (26.8) 21 (48.8) 17 (45.9)
2, n (%) 32 (18.0) 5 (11.9) 11 (19.6) 7 (16.3) 9 (24.3)
Use of direct medical care
Number of hospitalizations, mean  SD 0.32  0.6 0.19  0.5 0.32  0.6 0.42  0.5 0.34  0.6
Number of outpatient treatments and procedures,
mean  SD
2.02  2.1 1.31  1.4 1.88  2.0 2.40  2.2 2.61  2.4
Number of assistive devices, mean  SD 1.19  1.1 0.93  0.7 0.86  0.6 1.51  1.3 1.61  1.4
Number of medications, mean  SD 3.79  1.5 3.50  1.5 3.98  1.3 3.70  1.4 3.92  1.9
Informal caregiving hours per week, mean  SD 20.70  24.0 14.09  25.6 17.11  21.6 27.75  24.2 25.38  23.3
Differences between quartiles of Dependence Scale significant at Po .05;  .01.
SD5 standard deviation.
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associated with the DS; a 1-point increase on the DS was
associated with a $1,690 increase in informal costs.
DISCUSSION
In this study, the incremental effect of patients’ dependence
on total costs of care and on two main component costs
(direct medical care costs and informal caregiving costs)
were estimated in a sample of patients in early stages of AD,
controlling for patient’s function. Patients’ dependence on
others was measured using the DS and patients’ function
using the BDRS. As expected, as patients’ dependence in-
creased, all aspects of costs increased substantially. Similar
to previous studies, patients’ function was independently
associated with costs. It was found that function and de-
pendence were both significantly associated with total costs
yet related differently to direct medical care costs and in-
formal caregiving costs. Poorer function was associated
with higher direct medical care costs, whereas more-severe
levels of dependence were associated with higher informal
caregiving costs. These results confirm that BDRS and DS
represent distinct components of disability in AD, suggest
that measures of patients’ function and dependence provide
unique information for explaining variations in costs of
care for patients with AD, and highlight the value of mea-
suring both constructs in economics and outcomes research.
These results have substantial policy implications.
They provide information for deriving estimates of poten-
tial cost savings if interventions are developed that aim to
improve patients’ function and lessen their dependence on
others. Earlier studies have estimated that BDRS and DS
scores worsen by 1.5 points and 1 point per year, respec-
tively.6,30 Results in this study suggest that small differences
in patients’ function and dependence may be associated
with large differences in medical care costs and informal
caregiving costs. For example, an intervention that delays
the worsening of BDRS score by 1 point in patients with AD
could be expected to yield average savings of $1,406 per
year in direct medical costs. An intervention that delays the
worsening of DS score by 1 point in patients with AD could
be expected to yield average savings of $1,690 per year in
informal caregiving costs. Thus, the choice of interventions
that aim to delay a patient moving to higher levels of
functional impairment or dependence on others have the
potential to yield substantial economic benefit. Comparison
of the strengths of the effects of BDRS and DS on different
cost components suggests that success of the interventions
to control costs and improve patient outcome depends on













Direct Medical Cost Informal Cost
2 3 4
Figure 1. Direct medical costs included costs of hospitalization,
outpatient treatment and procedures, assistive devices, and med-
ications, with prices obtained from public databases. Informal
costs were estimated by costs of informal caregiving time for
activities of daily living and instrumental activities of daily living
obtained from up to three caregivers for each patient. National
average hourly earning for all private industries was used as the
hourly wage rate to estimate informal caregiving costs.
Table 2. Generalized Linear Models of Direct Medical
































































 809.44  795.75  870.14
Po .05;  .01.
wDirect medical costs included costs of hospitalization, outpatient treatments
and procedures, assistive devices, and medications, with prices obtained from
public databases.
z Informal costs were estimated by costs of informal caregiving time for ac-
tivities of daily living and instrumental activities of daily living obtained from
up to three caregivers for each patient. National average hourly earning for all
private industries was used as the hourly wage rate to estimate informal
caregiving costs.
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The potential cost savings estimated are generated from
a sample of mildly demented patients. Although most cost
savings may not be realized immediately, a delay in disease
progression for patients at early stages of the disease may
yield greater cost savings than the same delay experienced
by patients at later disease stages. Because subjects have
been followed closely in this study, future work will address
questions of lifetime cost savings more appropriately by
using longitudinal analyses. Longitudinal analyses also will
confirm whether the relationships between BDRS and DS
and different cost components are consistent over time.
This study focused on direct medical costs and informal
costs. An important component of costs that is not included
in this analysis is nonmedical costs, which include, among
others, costs for home health aides, respite care, and adult
day care. Previous studies have shown that the proportion
of total costs attributable to nonmedical costs is smaller
than direct medical costs and informal costs.31 Therefore,
the effects of excluding nonmedical costs from the total cost
estimations should be minimal. Results from secondary an-
alyses, including use of nonmedical care as an explanatory
variable, showed that it was not significantly associated
with direct medical care costs or informal costs. Indeed, few
patients in this sample (12.3%, n522) reported using non-
medical care, precluding detailed analysis of its relationship
to patients’ dependence. Bivariate analysis of the relation-
ship between use (and costs) of nonmedical care and
patients’ dependence showed that there was minimal use
(and costs) of nonmedical care for patients at mild levels of
dependence and that costs did not begin to rise until mod-
erate levels of dependence were reached. This suggests that,
over time, as patients’ dependence increases, it is likely that
use and costs of nonmedical care will increase. Although
the magnitude of these costs may continue to be smaller
than direct medical care and informal care costs, they are
nevertheless important for patients and families. Future
longitudinal analyses will examine use and costs of
nonmedical care in more detail.
Several limitations of this study should be noted. First,
data reported here are cross-sectional; therefore results can
be interpreted only as associations. Although poorer func-
tion and dependence may lead to higher costs, it also is
possible that low spending on health care indicates insuffi-
cient medical care and results in poor health. In this sample
of patients with relatively high education levels, however,
the latter explanation is less likely. Second, aside from
the patient characteristics included in the model, other vari-
ables may be associated with higher costs, although the
focus of this study was to examine whether the dependence
scale could explain variations in costs, and identifying pre-
dictors of informal care was beyond the scope of this article.
Third, patients and informants, most of whom were the
patients’ primary caregivers reported data on patients’
healthcare costs from this study. Studies have shown that
caregivers are able to accurately report medical information
of their care recipients.32,33 There is no reason to believe
that this sample was systematically different, although it is
possible that there were additional costs important to
patients and families beyond the resource items collected.
The cost estimates were from society’s perspective, because
all costs, regardless of the payer, were collected. Fourth,
patients were selected from tertiary care university hospitals
and specialized diagnostic and treatment centers and thus
represent a nonrandom sample of those affected by AD in
the population. The patients in the sample were predom-
inantly white and highly educated. Caution is needed in
generalizing the results of this study to patients with lower
levels of education and income and to nonwhite patients.
Future research will need to examine the relationship
between costs and the potential variables in samples that
are more representative of the general population, but
because patients were drawn from multiple locations,
generalizability of the findings is enhanced. Substantial
cost differences were found across sites. This result is con-
sistent with regional differences in health services use and
costs documented in the literature34 and more specifically a
recent study on service use and costs of patients with AD.35
Because different sites were included in these studies, the
results of the current study are not directly comparable with
those of these studies. Further investigations are needed to
examine whether variations in use and costs reflect differ-
ences in regional preferences, availability of or access to
services, ethnic and cultural differences, or socioeconomic
factors.
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